Skip to Content
Søk Menu

Real-World Outcomes on ADHD medication & Introducing A new methylphenidate option for child and adolescent patients

We would like to invite you to a Nordic live webinar with focus on Real-World Evidence and Tuzulby(Methylphenidat), a new methylphenidate treatment option in ADHD, for child and adolescent patients.

Program

17.00 - 17.15
Welcome and introduction Rikard Ekberg (Business Unit Lead, Neuraxpharm Sweden AB) and Nanna Cornelius (Medical Science Lead, Neuraxpharm Sweden AB).

17.15 - 17.45 | Prof. Henrik Larsson
Henrik Larsson; Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on real-world outcomes.

17.45 - 18.15 | Dr. Michael Feld
Michael Feld; Real-world insights on Tuzulby – The new prolonged-release chewable tablet

18.15 - 18.30
Q&A

Speakers

Henrik Larsson

Editor in Chief of JCPP Advances, and Professor of Psychiatric Epidemiology at Örebro University and Karolinska Institutet, Sweden.
Michael Feld

Child and Adolescent Psychiatrist, Northbrook Illinois. Michael is a specialist in child, adolescent and adult psychiatry in Northbrook Illinois. He is particularly recognized for his expertise in the diagnosis and treatment of ADHD and related conditions in both children and adults. He has extensive experience with ADHD and has often acted as an expert regarding new treatment methods.

Sign up

Registration must comply with the regulations of your local hospital or departmental management. Participation is free of charge and is limited to physicians, nurses, and other healthcare professionals. 

By registering, you confirm that you have permission to do so in accordance with the regulations of your local hospital or your departmental management.

Sign up here

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top